Breastcancer Clinical Trial
Official title:
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
Verified date | March 2022 |
Source | Athenex, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, open-label, single-arm PK study in patients for whom paclitaxel treatment is indicated.
Status | Completed |
Enrollment | 28 |
Est. completion date | November 22, 2018 |
Est. primary completion date | November 22, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed written informed consent 2. Women =18 years of age on day of consent 3. Breast cancer in patients for whom treatment with IV paclitaxel at 80 mg/m2 as monotherapy has been recommended by their oncologist 4. Measurable disease as per RECIST v1.1 criteria 5. Adequate hematological status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) maintain: - Absolute neutrophil count (ANC) =1.5 x 10^9/L - Platelet count =100 x 10^9/L - Hemoglobin (Hgb) =9 g/dL 6. Adequate liver function - Total bilirubin of =1.5 mg/dL - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3 x upper limit of normal (ULN) or =5 x ULN if liver metastasis is present - Alkaline phosphatase (ALP) =3 x ULN or =5 x ULN if bone metastasis is present - Gamma glutamyl transferase (GGT) <10 x ULN 7. Adequate renal function as demonstrated by serum creatinine =1.5 x ULN 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 9. Life expectancy of at least 3 months 10. Willing to fast for 6 hours before and 2 hours after Oraxol administration on all treatment days 11. Willing to abstain from alcohol consumption for 3 days before the first dose of study drug through the completion of the second inpatient PK sampling period 12. Willing to refrain from caffeine consumption for 12 hours before each inpatient dosing period through the completion of protocol-specified PK sampling for that week 13. Subjects must be postmenopausal (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment. 14. Subjects who are of childbearing potential must have a negative serum pregnancy test at Screening and within 96 hours before dosing. Exclusion Criteria: 1. Have not recovered to = Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs) 2. If previously treated with a taxane (paclitaxel or docetaxel) as part of anthracycline-based adjuvant chemotherapy or for metastatic disease, the subject relapsed less than 1 year following treatment 3. Subjects unable to swallow study medication in its intact form or have clinically significant malabsorption syndrome 4. Only site of metastatic disease is unmeasurable according to RECIST v1.1 criteria 5. Known CNS metastasis, including leptomeningeal involvement 6. Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer 7. Are currently receiving other medications intended for the treatment of their malignancy 8. Women who are pregnant or breastfeeding 9. Taking prohibited medications: 10. Use of warfarin. Subjects receiving warfarin who are otherwise eligible and who may be appropriately managed with low molecular weight heparin, in the opinion of the Investigator, may be enrolled in the study provided they are switched to low molecular weight heparin at least 7 days prior to receiving study treatment. 11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements 12. Known allergic reaction or intolerance to study medication components 13. Known allergic reaction or intolerance to contrast media 14. Subjects who, in the Investigator's opinion, are not suitable for participation in this study |
Country | Name | City | State |
---|---|---|---|
Taiwan | China Medical University Hospital | Taichung | |
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | Shuang Ho Hospital | Taipei | |
Taiwan | Taipei Medical University Hospital | Taipei | |
Taiwan | Taipei Veterans Generla Hospital | Taipei | |
Taiwan | Tri-Service General Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
Athenex, Inc. | PharmaEssentia |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PK Parameters for paclitaxel_AUC (0-52) | PK parameters were summarized using the mean, SD | PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4 | |
Primary | PK Parameters for paclitaxel_Cmax | PK parameters were summarized using the mean, SD | PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4 | |
Primary | PK Parameters for paclitaxel_Ctrough(24) | PK parameters were summarized using the mean, SD | PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4 | |
Primary | PK Parameters for paclitaxel_Ctrough(48) | PK parameters were summarized using the mean, SD | PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4 | |
Primary | PK Parameters for paclitaxel_Cmax(0-24) | PK parameters were summarized using the mean, SD | PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4 | |
Primary | PK Parameters for paclitaxel_Cmax(24-48) | PK parameters were summarized using the mean, SD | PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4 | |
Primary | PK Parameters for paclitaxel_Cmax(48-52) | PK parameters were summarized using the mean, SD | PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4 | |
Primary | PK Parameters for paclitaxel_tmax(0-24) | PK parameters were summarized using the median, minimum, maximum | PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4 | |
Primary | PK Parameters for paclitaxel_tmax(24-48) | PK parameters were summarized using the median, minimum, maximum | PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4 | |
Primary | PK Parameters for paclitaxel_tmax(48-52) | PK parameters were summarized using the median, minimum, maximum | PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4 | |
Secondary | Safety of Oraxol in Breast Cancer Patients | Safety was assessed by evaluating treatment-emergent adverse events (TEAEs) including SAEs, laboratory evaluations (hematology, blood chemistry, and urinalysis), vital signs, physical examinations, and electrocardiograms (ECGs). | From enrollment through study completion, approximately 17 weeks | |
Secondary | Response Rate | Tumor response rate and 95% confidence interval (CI) were evaluated based on the number of subjects with any post-baseline CR or PR per RECIST 1.1 as assessed by the Investigator and the ICRRC. | From baseline through study completion, around 21 weeks | |
Secondary | Progression-free Survival | PFS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.
The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation |
From baseline through study completion, around 21 weeks | |
Secondary | Overall Survival | OS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.
The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation |
From baseline through study completion, around 21 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02944604 -
The Efficacy and Safety of PEG-rhG-CSF(Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy
|
Phase 4 | |
Completed |
NCT03012152 -
A Comparative Study Between Oncoplastic Breast Surgery and Standard Conservative Surgery:Margin Status and Patient Satisfaction
|
N/A | |
Terminated |
NCT04168957 -
An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
|
Phase 1 | |
Recruiting |
NCT02967146 -
Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Axillary Dissection for Breast Cancer
|
Phase 3 | |
Completed |
NCT02958332 -
Effects of a Videogame-based Program on Women With Lymphedema Secondary to Breast Cancer
|
N/A | |
Completed |
NCT03030677 -
Establishing Technique for PECS2 Catheter Insertion
|
N/A | |
Completed |
NCT03066947 -
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT02992574 -
Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer
|
N/A | |
Completed |
NCT02964234 -
Empowering Latinas to Obtain Breast Cancer Screenings
|
N/A | |
Completed |
NCT02996240 -
Breast, Omega 3 Free Fatty Acid, Ph 0
|
N/A | |
Completed |
NCT03010371 -
Presential Vs Online Group-based Psychosocial Treatment for Breast Cancer Survivors.
|
N/A | |
Completed |
NCT02209857 -
The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy
|
N/A | |
Completed |
NCT03014076 -
Immunotherapy Vaccine and Herceptin in Breast Cancer
|
Phase 1 | |
Terminated |
NCT02975128 -
Minimal Invasive Breast Cancer Excision Using the Breast Lesion Excision System Under Ultrasound Guidance
|
N/A | |
Active, not recruiting |
NCT03121248 -
Outcome of 15 Versus 5 Fractions in Adjuvant Breast Radiotherapy in Women Over 65 Years
|
N/A | |
Active, not recruiting |
NCT02997384 -
Feasibility of Breast Cancer Risk Evaluation in Women From the General Population
|
N/A | |
Completed |
NCT03012893 -
Identification of C7; Evaluations of 2 Sonographic Methods Using a Transverse and a Sagittal Scan.
|
N/A | |
Completed |
NCT03023007 -
Study Evaluating the Efficacy of Loco-regional Anaesthesia PECS on Chronic Pain of a Mastectomy
|
N/A | |
Completed |
NCT04993040 -
A PK Study of Oraxol in Breast Cancer Patients
|
Phase 1 | |
Completed |
NCT02992067 -
CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer
|